Medication & safetyReviewed July 2026

Can you take Entresto and carvedilol together?

Short answer

Medication question

Yes — Entresto (sacubitril/valsartan) and carvedilol are frequently used together in the management of heart failure with reduced ejection fraction under medical supervision. Both medications affect blood pressure and heart rate, so the combination requires careful prescriber oversight and individualized dose titration. Do not combine, stop, or adjust either drug without explicit guidance from your cardiologist or prescriber.

This is a general research summary, not medical advice. A pharmacist can confirm it for your situation.

Reviewed
Dr. Chet Tharpe, MD
Independent
No affiliate agenda — a straight answer
Non-official
Confirm with your pharmacist
Sourced
From reputable public references

Here's the nuance

A one-liner rarely tells the whole story. This is the honest detail behind the short answer above.

Entresto (sacubitril/valsartan) is an angiotensin receptor-neprilysin inhibitor (ARNI) approved for chronic heart failure with reduced ejection fraction (HFrEF). Carvedilol is a non-selective beta-blocker with alpha-1 blocking properties, also used in HFrEF. Major heart failure guidelines — including those from the American College of Cardiology and the American Heart Association — support the use of both drug classes together as part of guideline-directed medical therapy for HFrEF.

The combination is clinically logical: Entresto addresses the neurohormonal overactivation from the renin-angiotensin-aldosterone system side, while carvedilol addresses excess sympathetic nervous system activation — both of which drive adverse cardiac remodeling in heart failure. Clinical trials have used both classes together. Real-world practice commonly involves Entresto and carvedilol (or other beta-blockers) prescribed simultaneously.

However, both medications lower blood pressure, and carvedilol also slows heart rate. The combination can cause additive hypotension (low blood pressure) and bradycardia (slow heart rate), especially during dose initiation or uptitration. This is why heart failure pharmacotherapy is titrated slowly and carefully by a cardiologist or heart failure specialist — starting doses are low and increased gradually as tolerated, with blood pressure and heart rate monitoring at each step.

If you are currently taking one of these medications and your prescriber is considering adding the other, expect a gradual titration process with follow-up visits. If you are already on both and experiencing dizziness, lightheadedness, fainting, or a very slow pulse, contact your prescriber promptly — do not stop either medication without guidance, as abrupt discontinuation of a beta-blocker or ARNI can be harmful in heart failure. All dose decisions belong with the prescriber who knows your cardiac function, kidney function, and complete medication list.

The key points

The handful of things that decide the answer — skim these if you only read one section.

1

Both are standard heart failure medications often used together

ACC/AHA heart failure guidelines support combining ARNIs (Entresto) and beta-blockers (carvedilol) in HFrEF — these are two of the cornerstone drug classes in guideline-directed medical therapy. Their combination is clinically well-established.

2

Additive blood pressure lowering requires monitoring

Both Entresto and carvedilol lower blood pressure through different mechanisms. Carvedilol also slows heart rate. The combination can cause symptomatic hypotension or bradycardia, particularly when doses are being adjusted. Regular monitoring by your prescriber is essential.

3

Dose titration must be done slowly and under medical supervision

Heart failure medications are started at low doses and increased gradually. Adding Entresto to an existing beta-blocker regimen (or vice versa) is done incrementally, with blood pressure and heart rate checks at each step. Do not adjust doses on your own.

4

Do not stop either medication abruptly

Abrupt discontinuation of carvedilol or Entresto in heart failure can cause rebound worsening of cardiac function. If you need to stop either medication — for any reason — this should be done under medical supervision with a tapering plan.

5

Kidney function monitoring is important with Entresto

The valsartan component of Entresto affects kidney function, particularly in patients with pre-existing kidney disease. Regular renal function monitoring is standard when on Entresto. Your prescriber will factor this into how carvedilol doses are adjusted alongside it.

Please read before acting on this

General information — not medical advice

This page is a general research summary about the medication in question. It does not account for your specific health, other medicines you take, or your dose, and it can go out of date. It is not medical advice, a prescription, or a substitute for professional judgment.

Ask your pharmacist or prescriber before starting, stopping, changing, or continuing any medication — they can check it against your situation in minutes.

Frequently Asked Questions

Reviewed by

Dr. Chet TharpeMD

Last reviewed July 2026

If an allergen is behind it

Stop guessing which trigger is behind it

If your symptoms keep coming back and an allergen might be the cause, testing tells you what you actually react to. Curex offers at-home allergy testing and immunotherapy so you can treat the trigger, not just manage the symptom.

  • At-home allergy test kit — no clinic visit
  • Reviewed by board-certified allergists
  • Find the trigger instead of guessing
Explore allergy testingTesting identifies sensitivities — it doesn't answer this question for you, and it isn't medical care.

This content is for general informational purposes only. It is not medical advice, a prescription, or a substitute for professional judgment, and it does not account for your health, other medications, or dose. Always ask your pharmacist or prescriber before starting, stopping, or changing any medication.

Questions about Curex itself?

Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.